COVID-19: Information on ASPIRA LABS Operations

Click to Learn More
  • Home
  • OVA1 Products

OVA1 Products

Protein Biomarker Testing for Ovarian Cancer Risk


OVA1® and OVERA® are FDA-cleared blood tests with unparalleled abilities to detect ovarian cancer risk in women diagnosed with a pelvic mass. For women with an adnexal mass, OVA1®plus is a reflex process which first performs OVA1 and then performs OVERA if the OVA1 result is in the intermediate range.

OVA1 Plus Logo

OVA1plus

OVA1plus is a reflex process which performs OVA1 and OVERA, both FDA-cleared tests for women with adnexal masses. OVA1plus helps you further stratify your patient’s risk of malignancy for women with pelvic masses planned for surgery. Benefits of this enhanced test offering include; Reducing the falsely elevated rate by up to 50%, maintaining the high rate of detection (sensitivity) for ovarian cancer risk, continuing to provide confidence in low-risk results with a high negative predictive value, and increased specificity by up to 20%.

OVA1 Logo

OVA1

OVA1 is an FDA-cleared blood test with an unparalleled ability to detect ovarian cancer risk in women who are planned for surgery for a pelvic mass. OVA1, a first-generation Multivariate Index Assay (MIA), evaluates the levels of five ovarian cancer-associated markers in the blood and utilizes a sophisticated mathematical formula to combine these levels into a single ovarian cancer risk score. By incorporating multiple markers, OVA1 (MIA) is able to detect more ovarian cancers, including less common forms of cancer, than alternative testing modalities. Critically, OVA1 (MIA) can detect early-stage ovarian cancer which is associated with dramatically better survival rates. Given OVA1’s superior detection capabilities, a negative OVA1 (MIA) result is accompanied by a 98% likelihood that the woman being tested is in fact disease-free.

OVERA Logo

OVERA

OVERA, a second-generation Multivariate Index Assay (MIA2G), is an FDA-cleared blood test for women with a pelvic mass who are planned for surgery. OVERA (MIA2G) maintains the high level of ovarian cancer detection, across rare subtypes and including early-stage cancers, afforded by OVA1 (MIA). However, OVERA (MIA2G) incorporates different markers and a refined algorithm. OVERA (MIA2G) represents a significant improvement in positive predictive value, overall accuracy and a reduction in falsely elevated results and unnecessary referrals. With OVERA (MIA2G), healthcare providers can feel confident that they are using the best tool for ovarian cancer detection while minimizing the inefficiencies to the healthcare system and patient anxiety associated with falsely elevated results.